Evrenzo self attestation

Are you a Healthcare Professional?

This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.

I AM NOT A HEALTHCARE PROFESSIONAL
evrenzo leavingsoon

You are leaving the website

You are now leaving an Astellas Pharma Ltd. website.
Astellas bears no responsibility for the content of any 3rd party material
nor how it might be used. Click OK to proceed.

Non-dialysis-dependent

  • EVRENZO efficacy was comparable with ESA1,2

    Non dialysis dependent table
    Non-Dialysis Dependent 2

    The Phase Ill DOLOMITES study evaluated the efficacy and safety profile of EVRENZO compared to darbepoetin-alfa for the treatment of anaemia in NDD patients with stage 3-5 CKD. In the primary endpoint analysis, the study demonstrated non-inferiority of EVRENZO to darbepoetin-alfa in the proportion of patients achieving correction of Hb levels during the first 24 weeks of treatment (89.5% vs. 78%, respectively)2

    CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; EOT, end of treatment; Hb, haemoglobin; IDD, incident dialysis-dependent; NDD, non-dialysis-dependent.

    Reference

    • EVRENZO SmPC 09.2024 sect. 5.1
    • Barratt J, Andric B, Tataradze A et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES) Nephrol Dial Transplant. 2021;36(9):1616–1628.

  • EVRENZO reduced use of IV iron1,2

    Non dialysis dependent table

    Non-Dialysis Dependent 3

    CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent. IV, intravenous; IDD, incident dialysis-dependent; NDD, non-dialysis-dependent.

    References

    • EVRENZO SmPC 09.2024 sect. 5.1
    • Barratt J, Andric B, Tataradze A et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES) Nephrol Dial Transplant. 2021;36(9):1616–1628.

  • EVRENZO summary in NDD

    Non-Dialysis Dependent 4

     

    In non-dialysis-dependent CKD, EVRENZO can help your patients meet and maintain their Hb targets1

    • Hb correction and maintenance was statistically superior to placebo (p<0.0001) and comparable with ESA (p=0.844)1,2

    • EVRENZO treatment reduced the use of IV iron supplementation compared with treatment with ESA1,2

    CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous.

    Reference

    • EVRENZO SmPC 09.2024 sect. 5.1
    • Barratt J, Andric B, Tataradze A et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES) Nephrol Dial Transplant. 2021;36(9):1616–1628.